🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,265 results for “Gan” Clear

  1. probiotics, antibiotics or antidepressants

    The First People's Hospital of Lianyungang

    Irritable Bowel Syndrome

    phase 3 small molecule active

    1 trial

  2. recombinant human erythropoietin

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 3 small molecule active

    1 trial

  3. recombinant human thrombopoietin

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  4. rhTPO

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  5. the Shouhui Tongbian Capsule

    The First People's Hospital of Lianyungang

    OIC

    phase 3 small molecule active

    1 trial

  6. ticagrelor

    The First People's Hospital of Lianyungang

    Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  7. venetoclax

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  8. zilganersen

    IONIS PHARMACEUTICALS INC

    Alexander Disease

    phase 3 small molecule active

    1 trial

  9. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  10. "Endostar"

    The First People's Hospital of Lianyungang

    Esophageal

    phase 2 small molecule terminated

    1 trial

  11. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

  12. 0.9% sodium chloride

    The First People's Hospital of Lianyungang

    Kidney Disease, Chronic

    phase 2 small molecule active

    1 trial

  13. 177Lu-DOTA-EB-FAPI radionuclide therapy

    The First People's Hospital of Lianyungang

    Refractory Solid Tumor

    phase 2 small molecule completed

    1 trial

  14. 18F-92

    The First People's Hospital of Lianyungang

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  15. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  16. 225Ac-LNC1011

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  17. 3D hypoxia-preconditioned UC-MSC group

    The First People's Hospital of Lianyungang

    Severe Aplastic Anemia (SAA)

    phase 2 small molecule active

    1 trial

  18. 68Ga-DOTATATE and 68Ga-FAPI

    The First People's Hospital of Lianyungang

    Tumor Positron-Emission Tomography

    phase 2 small molecule completed

    1 trial

  19. 68Ga-FAP-CHX

    The First People's Hospital of Lianyungang

    Tumor

    phase 2 small molecule active

    1 trial

  20. 68Ga-G21

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  21. 68Ga-NY104 PET/CT

    The First People's Hospital of Lianyungang

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. A Master Ganoderma Detox Tea

    Hong Kong Baptist University

    Eczema

    phase 2 other active

    1 trial

  23. A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer

    Novartis Pharmaceuticals

    Metastatic neuroendocrine prostate cancer

    phase 2 other active

    1 trial

  24. AGN 211745

    Allergan Pharmaceuticals International Limited

    Choroid Neovascularization

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources